Peter M Irving

49PUBLICATIONS
233CO-AUTHORS
Immunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Wastewater treatment processesCancer therapy (excl. chemotherapy and radiation therapy)Social epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Jun 04, 2026
The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes.

|Mar 04, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.

Bruce E Sands, David B Clemow, Geert D'Haens

|Feb 08, 2026
Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.

Marla C Dubinsky, María Chaparro, Peter M Irving

|Jan 19, 2026
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis.

Stefan Schreiber, Silvio Danese, Jean-Frédéric Colombel

|Dec 25, 2025
Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.

Gordon W Moran, Shellie J Radford, Alissa Walsh

|Sep 26, 2025
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.

Andres Yarur, Peter Irving, Britta Siegmund

Pageof 9

Frequent Collaborators

10 joint publications

Nick Kennedy

10 joint publications

Mark Samaan

9 joint publications

Christopher Andrew Lamb

9 joint publications

Timothy Raine